166 related articles for article (PubMed ID: 17199133)
1. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
Shim HB; Lee JK; Jung TY; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
3. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
4. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia.
Lee SE; Chung JS; Han BK; Moon KH; Hwang SI; Lee HJ; Choe G; Hong SK
Urology; 2008 Mar; 71(3):395-8. PubMed ID: 18342171
[TBL] [Abstract][Full Text] [Related]
5. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
Bohnen AM; Groeneveld FP; Bosch JL
Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
[TBL] [Abstract][Full Text] [Related]
7. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
[TBL] [Abstract][Full Text] [Related]
9. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study.
Bosch JL; Bohnen AM; Groeneveld FP
Eur Urol; 2004 Dec; 46(6):753-9. PubMed ID: 15548443
[TBL] [Abstract][Full Text] [Related]
10. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
12. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
[TBL] [Abstract][Full Text] [Related]
13. [Urinary problems and prostate-specific antigen in a Norwegian normal population].
Eide IA; Angelsen A; Øverland GB; Vada K; Vatten L
Tidsskr Nor Laegeforen; 2001 Feb; 121(5):553-6. PubMed ID: 11301608
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Mills IW; Crossland A; Patel A; Ramonas H
Eur Urol; 2007 Aug; 52(2):503-9. PubMed ID: 17343981
[TBL] [Abstract][Full Text] [Related]
15. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Paick SH; Meehan A; Lee M; Penson DF; Wessells H
J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
Laniado ME; Ockrim JL; Marronaro A; Tubaro A; Carter SS
BJU Int; 2004 Dec; 94(9):1283-6. PubMed ID: 15610106
[TBL] [Abstract][Full Text] [Related]
17. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
18. Which obesity index best correlates with prostate volume, prostate-specific antigen, and lower urinary tract symptoms?
Yang HJ; Doo SW; Yang WJ; Song YS
Urology; 2012 Jul; 80(1):187-90. PubMed ID: 22626573
[TBL] [Abstract][Full Text] [Related]
19. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study.
Seo HK; Chung MK; Ryu SB; Lee KH;
Urology; 2007 Dec; 70(6):1109-12. PubMed ID: 18158028
[TBL] [Abstract][Full Text] [Related]
20. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
Pinsky PF; Kramer BS; Crawford ED; Grubb RL; Urban DA; Andriole GL; Chia D; Levin DL; Gohagan JK
Urology; 2006 Aug; 68(2):352-6. PubMed ID: 16904451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
